Soluble Tumor Necrosis Factor Receptor: EnbrelŪ (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation

This phase II trial is studying how well etanercept works in treating young patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant. Etanercept may be effective in treating patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • biological : etanercept
  • drug : methylprednisolone

Phase: Phase 2

Eligibility

Ages Eligible For Study:

1 Year - 17 Years

External Links

Stanford Medicine Resources:

Footer Links: